SNY - US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges | Benzinga
The U.S. Centers for Disease Control and Prevention (CDC) released more than 77,000 additional doses of Beyfortus (nirsevimab), a respiratory syncytial virus (RSV) drug developed in collaboration between Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN).
Beyfortus is a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease.
These additional doses will be distributed immediately to physicians and hospitals through the Vaccines for Children Program and commercial channels – improving ...